CONTINUITY BIOSCIENCES, LLC — Department of Health and Human Services SBIR Phase II: DIRECT TO PHASE II SBIR CONCEPT AWARD FOR NOVEL IONTOPHORETIC DRUG DELIVERY DEVICE FOR LOC
CONTINUITY BIOSCIENCES, LLC — SBIR Phase II award from Department of Health and Human Services.
Phase II SBIR prototype / development signal
- Phase II is where Department of Health and Human Services funds deeper R&D after feasibility. Incumbents with Phase II history are serious competitors on adjacent topics.
- Use this award as past-performance context and to map customer organizations for STRATFI/TACFI-style transition planning.
- At $2,995,581, this is a large obligation for typical SBIR Phase sizing — worth reviewing for scope breadth and teaming opportunity.
- Tagged technology areas: Human Performance & Medical. Follow those hubs for open topics and peer winners in the same cluster.
Summary
Continuity Biosciences, LLC received nearly $3 million from NIH for a Direct-to-Phase II SBIR award to develop a novel iontophoretic device that delivers drugs locally to treat oral cancer. The project focuses on creating an effective, targeted treatment option using electric current for drug delivery.
- Amount
- $2,995,581
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase II
- NAICS
- 541715 · RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY)
- Place of performance
- NC
- Period
- 2025-09-05 → 2027-09-04
Technology domains
Description
DIRECT TO PHASE II SBIR CONCEPT AWARD FOR NOVEL IONTOPHORETIC DRUG DELIVERY DEVICE FOR LOCAL AND EFFECTIVE TREATMENT OF ORAL CANCER